Tenure-track and full-time cancer specialist at the Institut Universitaire du Cancer de Toulouse (IUCT), Dr. Gomez-Roca completed his medical training in 2000 at the University of Buenos Aires with silver medal honors. He trained as internal medicine specialist at Instituto Universitario CEMIC at Buenos Aires (Argentina) and obtained his degree with honors in 2005. He continued his training in Medical Oncology and obtained his diploma at Paris-Sud Medical School (France) in 2007 and completed his Master in Oncology in 2008 at the same university.

During his oncology training, he discovered a passion for early drug development while working under the supervision of Jean-Charles Soria, from 2008 to 2011 at Gustave Roussy. He moved to Toulouse to join Jean- Pierre Delord’s team in 2012 and applied his expertise to help to develop one of the top -three early phase trial programs in France.

He’s currently a PhD candidate in Immuno-oncology at Pr Ayyoub’s laboratory and implied in the research of the complexity of microenvironment interactions between the primary tumor and metastases. Dr. Gomez-Roca is currently Co-Chair of the Clinical Research Unit at IUCT-Oncopole and leader in the Early Phase Unit with a focus on targeted therapies and immuno-oncology. His main research interests are early clinical development, phase I trials across solid tumors, innovative methods of evaluation of novel drugs’ clinical activity, personalized medicine and mechanisms of toxicities of new targeted agents and immunotherapies. He is also involved in translational research aspects related to interaction of immune-oncology agents and radiotherapy and interaction between primary tumors and metastases.

Dr Gomez-Roca is member of ESMO, ASCO and AACR. He contributed to more than 60 peer-reviewed publications including publications as first or second author in the Journal of Clinical Oncology and Annals of Oncology.

He currently serves as Chair of the Membership Committee (2024-2025) and is a member of the ESMO Council and the ESMO-Magnitude of Clinical Benefit Scale Working Group. He also leads the Patient Advocacy Group at the Société Française d’Immuno-Thérapie du Cancer (FITC) since 2019.